These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 17940970)

  • 1. Epitopes required for antibody-dependent enhancement of Ebola virus infection.
    Takada A; Ebihara H; Feldmann H; Geisbert TW; Kawaoka Y
    J Infect Dis; 2007 Nov; 196 Suppl 2():S347-56. PubMed ID: 17940970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectivity-enhancing antibodies to Ebola virus glycoprotein.
    Takada A; Watanabe S; Okazaki K; Kida H; Kawaoka Y
    J Virol; 2001 Mar; 75(5):2324-30. PubMed ID: 11160735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies.
    Qiu X; Alimonti JB; Melito PL; Fernando L; Ströher U; Jones SM
    Clin Immunol; 2011 Nov; 141(2):218-27. PubMed ID: 21925951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective efficacy of neutralizing antibodies against Ebola virus infection.
    Takada A; Ebihara H; Jones S; Feldmann H; Kawaoka Y
    Vaccine; 2007 Jan; 25(6):993-9. PubMed ID: 17055127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
    Usami K; Matsuno K; Igarashi M; Denda-Nagai K; Takada A; Irimura T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):74-8. PubMed ID: 21362405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
    Dowling W; Thompson E; Badger C; Mellquist JL; Garrison AR; Smith JM; Paragas J; Hogan RJ; Schmaljohn C
    J Virol; 2007 Feb; 81(4):1821-37. PubMed ID: 17151111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
    Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H
    J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSVΔG-ZEBOV-GP).
    Raabe V; Lai L; Morales J; Xu Y; Rouphael N; Davey RT; Mulligan MJ
    Vaccine; 2023 Feb; 41(8):1513-1523. PubMed ID: 36725433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current knowledge on lower virulence of Reston Ebola virus (in French: Connaissances actuelles sur la moindre virulence du virus Ebola Reston).
    Morikawa S; Saijo M; Kurane I
    Comp Immunol Microbiol Infect Dis; 2007 Sep; 30(5-6):391-8. PubMed ID: 17610952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlates of vaccine-induced protective immunity against Ebola virus disease.
    Medaglini D; Santoro F; Siegrist CA
    Semin Immunol; 2018 Oct; 39():65-72. PubMed ID: 30041831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections.
    Geisbert TW; Hensley LE; Geisbert JB; Jahrling PB
    Virology; 2002 Feb; 293(1):15-9. PubMed ID: 11853394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo characterization of recombinant Ebola viruses expressing enhanced green fluorescent protein.
    Ebihara H; Theriault S; Neumann G; Alimonti JB; Geisbert JB; Hensley LE; Groseth A; Jones SM; Geisbert TW; Kawaoka Y; Feldmann H
    J Infect Dis; 2007 Nov; 196 Suppl 2():S313-22. PubMed ID: 17940966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
    Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
    Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody responses to recombinant vesicular stomatitis virus-Zaire Ebolavirus vaccination for Ebola virus disease across doses and continents: 5-year durability.
    Huttner A; Agnandji ST; Engler O; Hooper JW; Kwilas S; Ricks K; Clements TL; Jonsdottir HR; Nakka SS; Rothenberger S; Kremsner P; Züst R; Medaglini D; Ottenhoff T; Harandi AM; Siegrist CA; ; ;
    Clin Microbiol Infect; 2023 Dec; 29(12):1587-1594. PubMed ID: 37661067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebola virus-like particles produced in insect cells exhibit dendritic cell stimulating activity and induce neutralizing antibodies.
    Ye L; Lin J; Sun Y; Bennouna S; Lo M; Wu Q; Bu Z; Pulendran B; Compans RW; Yang C
    Virology; 2006 Aug; 351(2):260-70. PubMed ID: 16678231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A complement component C1q-mediated mechanism of antibody-dependent enhancement of Ebola virus infection.
    Furuyama W; Nanbo A; Maruyama J; Marzi A; Takada A
    PLoS Negl Trop Dis; 2020 Sep; 14(9):e0008602. PubMed ID: 32886656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
    Yang ZY; Duckers HJ; Sullivan NJ; Sanchez A; Nabel EG; Nabel GJ
    Nat Med; 2000 Aug; 6(8):886-9. PubMed ID: 10932225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Filovirus infection of STAT-1 knockout mice.
    Raymond J; Bradfute S; Bray M
    J Infect Dis; 2011 Nov; 204 Suppl 3():S986-90. PubMed ID: 21987780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.